Advances in the management of heart failure: the role of ivabradine - Wikidata - wikimedia - TriplyDB

Advances in the management of heart failure: the role of ivabradine

Advances in the management of heart failure: the role of ivabradine

http://www.wikidata.org/entity/Q28072418

about

Influences of Ivabradine treatment on serum levels of cardiac biomarkers sST2, GDF-15, suPAR and H-FABP in patients with chronic heart failure.Inhibition of hyperpolarization-activated cyclic nucleotide-gated channels by β-blocker carvedilol

P2860

Q47193481-1B59E0F8-06D2-4CDA-BEF7-6904704D21AF Q57134916-45AC2B41-4884-43DA-AB02-0011369453D9

P2860

Advances in the management of heart failure: the role of ivabradine

http://www.wikidata.org/entity/Q28072418

description

2016 nî lūn-bûn

@nan

2016 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Advances in the management of heart failure: the role of ivabradine

@ast

Advances in the management of heart failure: the role of ivabradine

@en

Advances in the management of heart failure: the role of ivabradine

@nl

type

label

Advances in the management of heart failure: the role of ivabradine

@ast

Advances in the management of heart failure: the role of ivabradine

@en

Advances in the management of heart failure: the role of ivabradine

@nl

prefLabel

Advances in the management of heart failure: the role of ivabradine

@ast

Advances in the management of heart failure: the role of ivabradine

@en

Advances in the management of heart failure: the role of ivabradine

@nl

P1433

Q28072418-0611C297-38CC-4945-9DF7-4144AE12CC4D

P1476

Q28072418-5B22C27D-4420-4F74-A4A1-264494A37798

P2093

Q28072418-653562D6-AAED-422D-A8A0-3021C99EE59F

P275

Q28072418-EBD11466-532A-44AE-A8F7-8CBAB36B9475

P2860

Q28072418-00838BAA-3ADB-470B-BED8-736AF9E50104

Q28072418-030148CD-66EC-4811-A0EB-40207FD3B6A6

Q28072418-0627965A-2C55-43EC-AEEC-83403527B94A

Q28072418-07E3519D-229B-417A-BA58-65E8E952B092

Q28072418-09894E27-1B90-44EB-B3B9-2086A1BF5ED8

Q28072418-09A6EBC6-0041-4037-B63B-7F0E6538C178

Q28072418-0A7602D7-EC31-4AAB-918D-F4B7727F223E

Q28072418-0C02D565-1CBA-4D51-8885-F94E300F0D8C

Q28072418-0DB5C6AA-58F5-4460-A38E-73C7A94558D3

Q28072418-0EE6B132-2769-4501-9935-EC8E5123F6B4

P304

Q28072418-42D74A40-6A30-4E55-94F8-D81CC0267651

P31

Q28072418-550CFEE2-6889-4EE8-9578-BBE1DFDE9D6E

Q28072418-5ABDEB89-1C9A-4827-A5BE-949E5BA55795

P356

Q28072418-4A2A3C7A-E29A-4824-8D01-737BD9183F51

P407

Q28072418-C31EB1D3-A6C4-49EB-B0CF-ECAD6AF18BD9

P478

Q28072418-D6CF8817-888A-4202-8FFE-95986A5D343E

P50

Q28072418-0A2850F6-17A1-4E74-B701-B28D7824AF84

Q28072418-D95CC79C-68B3-4BE5-A943-F49EA4D7DE47

P5008

Q28072418-5D96A7EA-8821-46E6-86C8-53177C7096E6

P577

Q28072418-DA6B8179-4474-41E2-B9E3-DA994D0D5F67

P698

Q28072418-8AFF9442-B5A5-4DA3-AD43-A8010B533CCC

P921

Q28072418-74D93F3D-F772-4891-B30D-FFC60DBF0258

Q28072418-77911635-31BB-4915-A4B2-C1694A80CAD2

Q28072418-A8A834DB-AA1D-458B-9449-B6C811DF432C

P932

Q28072418-81F51BDA-2C51-41AE-B139-B995987A5DFB

P356

P1433

Vascular Health and Risk Management

P1476

Advances in the management of heart failure: the role of ivabradine

@en

P2093

Georg Stöckl

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

Effects of beta-blockers on heart failure with preserved ejection fraction: a meta-analysis

Health related quality of life in patients with congestive heart failure: comparison with other chronic diseases and relation to functional variables

2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines

Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study

Direct inhibition, but indirect sensitization of pacemaker activity to sympathetic tone by the interaction of endotoxin with HCN-channels.

Inhibition of cardiac pacemaker channel hHCN2 depends on intercalation of lipopolysaccharide into channel-containing membrane microdomains.

Ivabradine in combination with beta-blocker improves symptoms and quality of life in patients with stable angina pectoris: results from the ADDITIONS study.

Heart rate as an independent risk factor in patients with multiple organ dysfunction: a prospective, observational study.

Reducing elevated heart rate in patients with multiple organ dysfunction syndrome by the I (f) (funny channel current) inhibitor ivabradine : MODI (f)Y trial.

Cardiogenic shock due to tachycardiomyopathy after heart transplantation: successful treatment with ivabradine.

P304

453-470

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/VHRM.S90383

http://www.w3.org/2001/XMLSchema#string

P407

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Ursula Müller-Werdan

P5008

P577

2016-11-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27895488

http://www.w3.org/2001/XMLSchema#string

P921

Aparato circulatorio

heterocyclic compound

P932

5118024

http://www.w3.org/2001/XMLSchema#string